Profile data is unavailable for this security.
About the company
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
- Revenue in USD (TTM)235.64m
- Net income in USD21.59m
- Incorporated2010
- Employees185.00
- LocationPuma Biotechnology Inc10880 Wilshire Blvd., Suite 2150LOS ANGELES 90024United StatesUSA
- Phone+1 (424) 248-6500
- Fax+1 (424) 248-6501
- Websitehttps://www.pumabiotechnology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVITA Medical Inc | 50.14m | -35.38m | 224.97m | 207.00 | -- | 4.57 | -- | 4.49 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.40 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -42.49m | 227.02m | 32.00 | -- | 1.42 | -- | -- | -0.3343 | -0.3343 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -23.84 | -41.75 | -25.56 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Metagenomi Inc | 44.76m | -68.26m | 231.20m | 236.00 | -- | -- | -- | 5.17 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| G1 Therapeutics Inc | 82.51m | -47.97m | 232.23m | 100.00 | -- | 6.52 | -- | 2.81 | -0.953 | -0.953 | 1.53 | 0.6815 | 0.5332 | 0.5028 | 6.94 | 825,110.00 | -31.00 | -47.06 | -39.28 | -52.64 | 91.28 | -- | -58.13 | -268.59 | 3.45 | -5.22 | 0.593 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Eliem Therapeutics Inc | 0.00 | -35.12m | 235.28m | 9.00 | -- | 2.16 | -- | -- | -1.31 | -1.31 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -28.61 | -- | -29.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Codexis Inc | 70.14m | -76.24m | 235.66m | 174.00 | -- | 2.70 | -- | 3.36 | -1.12 | -1.12 | 1.03 | 1.24 | 0.3625 | 5.43 | 2.31 | 403,120.70 | -39.41 | -17.13 | -50.48 | -20.23 | 81.74 | 77.29 | -108.69 | -37.04 | 2.53 | -- | 0.00 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Puma Biotechnology Inc | 235.64m | 21.59m | 239.11m | 185.00 | 10.99 | 4.42 | 7.22 | 1.01 | 0.4515 | 0.4515 | 4.96 | 1.12 | 1.04 | 10.80 | 5.23 | 1,273,714.00 | 9.54 | -12.21 | 15.66 | -20.53 | 73.40 | 78.78 | 9.16 | -11.79 | 1.50 | 3.10 | 0.6509 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Veru Inc | 15.93m | -64.59m | 240.07m | 189.00 | -- | 4.65 | -- | 15.07 | -0.758 | -0.758 | 0.177 | 0.3525 | 0.1728 | 1.01 | 5.10 | 84,285.19 | -70.07 | -42.91 | -101.20 | -54.41 | 50.31 | 72.41 | -405.44 | -104.96 | 2.79 | -- | 0.1584 | -- | -58.59 | 0.5394 | -10.84 | -- | 67.39 | -- |
| AC Immune SA | 16.26m | -59.56m | 242.04m | 133.00 | -- | 1.37 | -- | 14.89 | -0.7049 | -0.7049 | 0.1914 | 1.78 | 0.0803 | -- | 1.92 | 122,224.80 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| XBiotech Inc | 0.00 | -24.56m | 244.22m | 82.00 | -- | 1.12 | -- | -- | -0.8068 | -0.8068 | 0.00 | 7.19 | 0.00 | -- | -- | 0.00 | -10.39 | 31.88 | -10.62 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.00 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Coherus Biosciences Inc | 257.24m | -237.89m | 246.29m | 306.00 | -- | -- | -- | 0.9574 | -2.56 | -2.56 | 2.74 | -1.72 | 0.4633 | 3.14 | 1.39 | 840,666.70 | -42.85 | -21.43 | -74.34 | -29.32 | 38.19 | 79.01 | -92.48 | -36.56 | 1.24 | -4.77 | 1.69 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Fennec Pharmaceuticals Inc | 21.25m | -16.05m | 246.34m | 36.00 | -- | -- | -- | 11.59 | -0.6042 | -0.6042 | 0.7994 | -0.43 | 0.79 | 0.9217 | 4.10 | -- | -59.64 | -73.43 | -77.06 | -84.32 | 94.08 | -- | -75.50 | -383.28 | 3.27 | -3.90 | 1.63 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -37.94m | 247.40m | 42.00 | -- | 19.24 | -- | -- | -1.31 | -1.31 | 0.00 | 0.4381 | 0.00 | -- | -- | 0.00 | -63.82 | -- | -76.57 | -- | -- | -- | -- | -- | -- | -73.91 | 0.6254 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Century Therapeutics Inc | 2.24m | -136.67m | 248.54m | 152.00 | -- | 0.9797 | -- | 111.20 | -2.30 | -2.30 | 0.0377 | 3.06 | 0.0053 | -- | -- | 14,703.95 | -32.26 | -- | -34.19 | -- | -- | -- | -6,115.12 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| TriSalus Life Sciences Inc | 18.51m | -63.28m | 249.92m | 112.00 | -- | -- | -- | 13.50 | -1.84 | -1.84 | 0.5991 | -0.982 | 0.7758 | 1.30 | 7.24 | 165,267.90 | -247.43 | -- | -17,440.77 | -- | 85.93 | -- | -318.95 | -- | 1.25 | -13.69 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -37.54m | 250.14m | 10.00 | -- | 2.08 | -- | -- | -0.6375 | -0.6375 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -22.78 | -36.79 | -25.71 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1123 | -- | -- | -- | 39.47 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Puma Biotechnology Inc's reporting currency: US Dollar USD
40.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 3.79m | 7.86% |
| Millennium Management LLCas of 31 Dec 2023 | 3.16m | 6.56% |
| Camber Capital Management LPas of 31 Dec 2023 | 2.81m | 5.82% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 1.92m | 3.98% |
| Athyrium Capital Management LPas of 31 Dec 2023 | 1.79m | 3.72% |
| Eversept Partners LPas of 31 Dec 2023 | 1.70m | 3.52% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 1.67m | 3.47% |
| Great Point Partners LLCas of 31 Dec 2023 | 1.09m | 2.27% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.00m | 2.08% |
| GlobeFlex Capital LPas of 31 Dec 2023 | 538.56k | 1.12% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
